[at Wall St. Cheat Sheet] – Merck has filed a lawsuit against Actavis on claims that Actavis has been marketing a generic version of NuvaRing before Merck’s patent is set to expire.
Read more on this.
Merck & Co. Inc. (MRK), with a current value of $144.37B, opened at $49.43.
Today’s price range has been between $49.23 and $49.67 per share with a one year range of $40.02 to $50.42.
MRK shares are currently priced at 14.10x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 4.14x forward p/e ratio.
The company pays shareholders $1.76 per share annually in dividends, yielding 3.60%.
According to a consensus of 16 analysts, the earnings estimate of $0.88 per share would be $0.05 better than the year-ago quarter and a $0.03 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $3.50, which would be a $0.32 worse when compared to the last year’s annual results.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $11.39 Billion. If realized, that would be a 2.98% decrease over the year-ago quarter.
More recently, MKM Partners upgraded MRK from Neutral to Buy (Nov 20, 2012). Previously, MP Advisors upgraded MRK from Market Perform to Outperform.
When considering if perhaps the stock is under or overvalued, the average price target is $51.22, which is 3.62% above where the stock opened this morning.
Merck & Co. Inc. (NYSE:MRK), provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health and consumer care products worldwide. It offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of many human disorders.
Tag Helper ~ Stock Code: MRK | Common Company name: Merck | Full Company name: Merck & Co. Inc. (NYSE:MRK) .